Anti-inflammatory agents
OwnerJeffrey Ravetch, Robert Anthony +2inventors
InventorsJeffrey Ravetch, Robert Anthony, Toshihiko Kobayashi, Fredrik Wermeling
Life of this patent
Estimating the term…
Abstract
This invention concerns anti-inflammatory agents and methods for treating inflammatory disorders. Also disclosed are methods for identifying or evaluating anti-inflammatory agents or compositions.
Claims49
A method of producing immunosuppressive cells, comprising,
- contacting a plurality of myeloid cells from a donor mammal with a polypeptide composition having a polypeptide containing a Fc region that has a N-linked biantennary oligosaccharide having a terminal sialic acid connected to galactose by an α 2,6 linkage for a period of time;
- and
- isolating or enriching macrophages or dendritic cells from the plurality of cells to obtain immunosuppressive cells,
- wherein, once administered to a recipient mammal, the immunosuppressive cells up-regulate expression of a Th2 cytokine in the recipient mammal.
(canceled)
-8. (canceled)
A composition comprising
- a plurality of isolated myeloid cells;
- and
- a polypeptide containing a Fc region that has a N-linked biantennary oligosaccharide having a terminal sialic acid connected to galactose by an α 2,6 linkage.
A method of producing immunosuppressive cells, comprising,
- contacting a plurality of myeloid cells from a donor mammal with an IL-33 receptor agonist for a period of time;
- and,
- isolating or enriching basophils from the plurality of cells to obtain immunosuppressive cells.
-15. (canceled)
(canceled)
A composition comprising a plurality of myeloid cells and a protein having the sequence of SEQ ID NO:
- 1 or 2.
A method for treating an inflammatory disorder in a subject in need thereof, comprising administering to the subject a composition comprising a population of cells that effects an increase in the level of FcγRIIB expressed on the surface of IL-4Rα+ effector macrophages of the subject.
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating an inflammatory disorder in a subject in need thereof, comprising administering to the subject an agent that increases the expression level of IL-33 or IL-4 in the subject, wherein the agent does not bind to DC-SIGN.
-55. (canceled)
A method for identifying a candidate compound useful for treating an inflammatory disorder, the method comprising:
- (a) contacting a test compound with an indicator cell comprising an IL-33 expression element;
- (b) measuring an expression level of the IL-33 expression element in the indicator cell in the presence of the test compound;
- and
- (c) selecting the test compound as a candidate compound useful for treating the inflammatory disorder if the expression level measure in the presence of the compound is higher than a control level, thereby identifying the candidate compound.
A method for measuring the anti-inflammatory activity of a DC-SIGN-binding composition comprising:
- (a) contacting the DC-SIGN-binding composition with a population of immune cells comprising DC-SIGN+ cells;
- and
- (b) measuring the expression level of IL-33 produced by the immune cells in the presence of the DC-SIGN-binding composition,
- wherein the expression level of IL-33 produced by the immune cells is a measure of the anti-inflammatory activity of the DC-SIGN binding composition.
A method for measuring the anti-inflammatory activity of a DC-SIGN-binding composition comprising
- (a) administering a DC-SIGN-binding composition to a subject;
- and
- (b) measuring the expression level of IL-4 or IL-33 present in a sample of the subject in the presence of the DC-SIGN-binding composition, wherein the expression level of IL-4 or IL-33 present in the sample is a measure of the anti-inflammatory activity of the DC-SIGN-binding composition.
Dependencies are inferred from the claim text.